PFIZER Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
PFIZER has one hundred and ninety-four approved drugs.
There are forty-seven US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and sixteen patent family members on PFIZER drugs in seventy countries and two hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for PFIZER
International Patents: | 1016 |
US Patents: | 47 |
Tradenames: | 159 |
Ingredients: | 130 |
NDAs: | 194 |
Drug Master File Entries: | 3 |
Patent Litigation for PFIZER: | See patent lawsuits for PFIZER |
PTAB Cases with PFIZER as petitioner: | See PTAB cases with PFIZER as petitioner |
Drugs and US Patents for PFIZER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | LORBRENA | lorlatinib | TABLET;ORAL | 210868-001 | Nov 2, 2018 | RX | Yes | No | 10,420,749 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Pfizer | PFIZER-E | erythromycin stearate | TABLET;ORAL | 061791-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pfizer | MODERIL | rescinnamine | TABLET;ORAL | 010686-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PFIZER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer Pharms | LOPID | gemfibrozil | CAPSULE;ORAL | 018422-001 | Approved Prior to Jan 1, 1982 | 3,674,836 | ⤷ Try a Trial |
Pfizer | ZYVOX | linezolid | SOLUTION;INTRAVENOUS | 021131-001 | Apr 18, 2000 | 6,559,305*PED | ⤷ Try a Trial |
Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-004 | Nov 19, 1991 | 4,743,450*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
International Patents for PFIZER Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 2767537 | ⤷ Try a Trial |
Japan | 6109874 | ⤷ Try a Trial |
Japan | 2015511581 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PFIZER Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0565634 | 06C0030 | France | ⤷ Try a Trial | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
1470124 | LUC00009 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PALBOCICLIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL , D'UN ESTER, D'UN AMIDE OU D'UN PROMEDICAMENT PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/16/1147 20161111 |
2170860 | 2090036-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: GLASDEGIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE MALEATE SALT; REG. NO/DATE: EU/1/20/1451 20200629 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.